$1.2
Live
In the last 1 year, Novo Nordisk A/s has given 283.9% return, outperforming this stock by 357.6%
1.67%
Downside
Day's Volatility :4.84%
Upside
3.23%
2.5%
Downside
52 Weeks Volatility :84.75%
Upside
84.35%
Period | I-mab | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -60.44% | 0.0% | 0.0% |
6 Months | -65.28% | 3.0% | -0.5% |
1 Year | -73.68% | 7.2% | 0.4% |
3 Years | -98.44% | 27.5% | 19.1% |
Market Capitalization | 160.3M |
Book Value | $29.48 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.6 |
Wall Street Target Price | 28.85 |
Profit Margin | 0.0% |
Operating Margin TTM | 679.87% |
Return On Assets TTM | -25.36% |
Return On Equity TTM | -66.16% |
Revenue TTM | -253.8M |
Revenue Per Share TTM | -3.06 |
Quarterly Revenue Growth YOY | -62.1% |
Gross Profit TTM | 41.6M |
EBITDA | -1.9B |
Diluted Eps TTM | -3.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 2304.17%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 11.6M | - |
Net Income | -298.2M | - |
Net Profit Margin | -2.6K% | - |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 53.8M | ↑ 365.39% |
Net Income | -402.8M | ↑ 35.07% |
Net Profit Margin | -749.02% | ↑ 1831.8% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 30.0M | ↓ 44.22% |
Net Income | -1.5B | ↑ 260.43% |
Net Profit Margin | -4.8K% | ↓ 4090.81% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 5042.23% |
Net Income | 470.9M | ↓ 132.43% |
Net Profit Margin | 30.53% | ↑ 4870.36% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 13.8M | ↓ 94.29% |
Net Income | -365.9M | ↓ 595.11% |
Net Profit Margin | -2.6K% | ↓ 2679.23% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | -32.1M | ↓ 351.7% |
Net Income | -349.7M | ↑ 3.44% |
Net Profit Margin | 1.1K% | ↑ 3737.25% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | -1.8B | - |
Net Income | -3.0B | - |
Net Profit Margin | 168.77% | - |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | - |
Total Liabilities | 1.3B | - |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 131.72% |
Total Liabilities | 3.3B | ↑ 151.37% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 26.87% |
Total Liabilities | 3.8B | ↑ 13.25% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 6.3B | ↑ 264.52% |
Total Liabilities | 706.6M | ↓ 81.27% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 879.0M | ↓ 11.57% |
Total Liabilities | 163.5M | ↑ 47.41% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 590.7M | ↓ 27.27% |
Total Liabilities | 154.5M | ↑ 2.28% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 745.0M | - |
Total Liabilities | 145.6M | - |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.0B | ↑ 0.0% |
Total Liabilities | 975.5M | ↑ 0.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 590.7M | ↓ 18.39% |
Total Liabilities | 154.5M | ↑ 9.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 484.2M | - |
Total Liabilities | 146.8M | - |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -252.2M | - |
Investing Cash Flow | -157.7M | - |
Financing Cash Flow | 758.6M | - |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -280.7M | ↑ 11.32% |
Investing Cash Flow | 9.5M | ↓ 106.03% |
Financing Cash Flow | 1.5B | ↑ 95.06% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -868.0M | ↑ 209.22% |
Investing Cash Flow | 212.5M | ↑ 2136.44% |
Financing Cash Flow | 152.7M | ↓ 89.68% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 433.6M | ↓ 149.95% |
Investing Cash Flow | -201.9M | ↓ 195.03% |
Financing Cash Flow | 3.4B | ↑ 2152.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -152.7M | ↓ 324.44% |
Investing Cash Flow | -114.1M | ↑ 260.18% |
Financing Cash Flow | 93.2M | ↓ 82.74% |
Q2 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.3M | ↑ 0.0% |
Investing Cash Flow | -29.5M | ↑ 0.0% |
Financing Cash Flow | 37.7M | ↑ 0.0% |
Q3 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.1M | ↑ 19.84% |
Investing Cash Flow | -26.8M | ↓ 9.32% |
Financing Cash Flow | 8.4M | ↓ 77.85% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.6M | ↑ 0.0% |
Investing Cash Flow | -27.1M | ↑ 0.0% |
Financing Cash Flow | 8.4M | ↑ 0.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -45.0M | ↑ 7.67% |
Investing Cash Flow | 39.3M | ↓ 244.39% |
Financing Cash Flow | 2.8M | ↓ 67.15% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -42.6M | ↑ 0.0% |
Investing Cash Flow | 37.3M | ↑ 0.0% |
Financing Cash Flow | 2.6M | ↑ 0.0% |
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() I-mab | -34.38% | -65.28% | -73.68% | -98.44% | -98.44% |
![]() Moderna, Inc. | -6.8% | -31.93% | -17.68% | 49.48% | 456.61% |
![]() Regeneron Pharmaceuticals, Inc. | -1.51% | 9.46% | 21.47% | 49.65% | 113.08% |
![]() Novo Nordisk A/s | 2.45% | 158.58% | 283.85% | 452.05% | 699.12% |
![]() Seagen, Inc. | 7.08% | 3.54% | 46.23% | 15.75% | 166.19% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 16.4% | 25.65% | 33.45% | 95.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() I-mab | NA | NA | NA | 0.0 | -0.66 | -0.25 | 0.0 | 29.48 |
![]() Moderna, Inc. | 39.67 | 39.67 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.65 | 21.65 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 44.47 | 44.47 | 2.03 | 3.32 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.47 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.73 | 26.73 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() I-mab | Buy | $160.3M | -98.44% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $39.4B | 456.61% | 39.67 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.3B | 113.08% | 21.65 | 33.93% |
![]() Novo Nordisk A/s | Buy | $423.8B | 699.12% | 44.47 | 33.4% |
![]() Seagen, Inc. | Hold | $38.9B | 166.19% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.9B | 95.64% | 26.73 | 35.4% |
Hillhouse Capital Advisors, Ltd.
Vanguard Group Inc
BlackRock Inc
Artal Group S A
Bank of America Corp
JPMorgan Chase & Co
I-mab’s price-to-earnings ratio stands at None
Read Morei-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm
Organization | I-mab |
Employees | 0 |
CEO | Dr. Jingwu Zhang Zang M.D., Ph.D. |
Industry | Health Technology |
Wearable Devices Ltd
$1.20
-4.0%
Barrett Business Services Inc
$1.20
-4.0%
Simplify Interest Rate Hedge Etf
$1.20
-4.0%
Invesco S&p Smallcap 600® Pure Value Etf
$1.20
-4.0%
American Century Quality Diversified International Etf
$1.20
-4.0%
Short Dow30 Proshares
$1.20
-4.0%
Franklin Street Properties Corp
$1.20
-4.0%
Nuveen Credit Strat Incm
$1.20
-4.0%
Ishares Morningstar Value Etf
$1.20
-4.0%